biostudies-literatureUnknown8(10)Geißler ALEGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based mutation profiles, EGFR promoter methylation and EGFR expression status as well as to E-cadherin expression. Moreover, tissue specimens of primary and/or recurrent tumors as well as liver and/or lung metastases of 25 CRC patients having received Cetuximab and/or Panitumumab were examined for the same molecular markers. In vitro and in situ analyses showed that EGFR promoter methylatiOncotarget17164-17190https://www.ebi.ac.uk/biostudies/studies/S-EPMC5370031biostudies-literatureATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.PMC5370031Geißler ALFichter CDWeddeling BMakowiec FWerner MLassmann SGeißler MKottmann DLutz LFritsch RfalseATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based mutation profiles, EGFR promoter methylation and EGFR expression status as well as to E-cadherin expression. Moreover, tissue specimens of primary and/or recurrent tumors as well as liver and/or lung metastases of 25 CRC patients having received Cetuximab and/or Panitumumab were examined for the same molecular markers. In vitro and in situ analyses showed that EGFR promoter methylati2017-01-01T00:00:00Z2017 Mar2026-05-30T13:07:18.325Z2019-03-27T02:39:47ZS-EPMC53700312819997910.18632/oncotarget.15211